In a research report published Monday, Brean Capital analyst Jason Wittes reiterated a Buy rating on shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) with a …
In a research report released Tuesday, Brean Capital analyst Jason Wittes assumed coverage on shares of Inovio Pharmaceuticals Inc (NASDAQ:INO), with a Buy rating …
Brean Capital analyst Jason Wittes was out with a research report, assuming coverage on shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX), with a Buy rating and price target of …
In a research report published Tuesday, Brean Capital analyst Jason Wittes assumed coverage on shares of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), with a Buy rating and price …
In a research report released Tuesday, Brean Capital analyst Jason Wittes downgraded shares of Osiris Therapeutics, Inc. (NASDAQ:OSIR) from a Hold to a Sell rating, …
In a research report issued today, Brean Capital analyst Jason Wittes maintained a Buy rating on NuVasive Inc (NASDAQ:NUVA) with a $53 price target, after …
